CLIN Clinigen Group Plc

TIDMCLIN

RNS Number : 4741T

Clinigen Group plc

24 November 2021

24(th) November 2021

Result of AGM and Board Change

Clinigen Group plc (AIM: CLIN, 'Clinigen' or 'the Group'), the global pharmaceutical and Services and Products company, held its Annual General Meeting ('AGM') today at which all resolutions were passed. Resolutions 1-13 were passed as Ordinary Resolutions and Resolutions 14 and 15 were passed as Special Resolutions.

A minority of shareholders opposed Resolutions 2 (Directors' Remuneration Report for year ended 30 June 2021), 7 (re-election of Anne Hyland), 8 (re-election of Alan Boyd), and 13 (authorise the Directors to allot shares pursuant to section 551). In accordance with the FRC Code of Corporate Governance the Board will be consulting with major shareholders in order to understand the reasons why votes of over 20% were cast against the resolutions, and an update on views received and actions taken will be published no later than six months after today's date. The vote for Resolution 2 was advisory only.

Full details of the poll results will be made available on Clinigen's website at www.clinigengroup.com .

As previously announced on August 3, Ian Nicholson has stepped down from the Board and Sharon Curran will take over as Chair of the Remuneration Committee with immediate effect.

Elmar Schnee, Chairman of Clinigen, said: "Ian has provided valuable guidance and support to the Clinigen Board since his appointment in 2012. We would like to thank him for his contribution and wish him well for the future."

- Ends -

Contact details

 
 Clinigen Group plc                               +44 (0) 1283 495010 
 Rob Fox, VP Investor Relations and Corporate     investors@clinigengroup.com 
  Development 
 
 Numis Securities Limited - Nominated Adviser     Tel: +44 (0) 20 7260 
  & Joint Broker                                   1000 
 James Black / Garry Levin / Freddie Barnfield    Clinigen@Numis.com 
 RBC Capital Markets - Joint Broker               Tel: +44 (0) 20 7653 
                                                   4000 
 Marcus Jackson / Elliot Thomas 
 
 Consilium Strategic Communications               Tel: +44 (0) 20 3709 
  Mary-Jane Elliott / Matthew Cole / Jessica       5700 Clinigen@consilium-comms.com 
  Hodgson 
 
 

Notes to Editors

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global, specialist pharmaceutical services and products platform focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time. The Group operates from sites in North America, Europe, Africa and the Asia Pacific.

Clinigen has more than 1,000 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 34 of the top 50 pharmaceutical companies; interacting with over 5,000 hospitals across more than 115 countries.

For more information on Clinigen, please visit http://www.clinigen.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGPPGWUGUPGGPC

(END) Dow Jones Newswires

November 24, 2021 07:05 ET (12:05 GMT)

Clinigen (LSE:CLIN)
Historical Stock Chart
From Mar 2024 to Apr 2024

Clinigen (LSE:CLIN)
Historical Stock Chart
From Apr 2023 to Apr 2024